We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.30 | 3.20 | 3.40 | 3.30 | 3.30 | 3.30 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.26 | 2.98M |
TIDMVAL
RNS Number : 6656J
ValiRx PLC
25 August 2021
25 August 20 21
ValiRx Plc
( " ValiRx" or the " Company ")
Appointment of Broker
ValiRx Plc (AIM: VAL), has appointed Cenkos Securities plc ("Cenkos") as its sole broker with immediate effect.
In connection with the appointment of Cenkos, the Company has granted Cenkos with a warrant over 3,902,949 ordinary shares in the Company exercisable at price of 22p, being the closing mid-price on 24 August 2021 ("Warrants"). The Warrants are exercisable in whole or in part for the period commencing 12 months after the commencement of their engagement and ending 60 months after their engagement.
Dr Kevin Cox, Chairman commented: "We are very much looking forward to working closely with the Cenkos growth companies team to help deliver and further develop the strategy we have been building over the last year. After a period of consolidation and stability, this is a natural evolution in our growth plans."
ValiRx plc Tel: +44 (0) 2476 796496 www.valirx.com Suzanne Dilly, CEO Suzanne.Dilly@valirx.com Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 Adviser) 088 Liam Murray / Jo Turner / Ludovico Lazzaretti Cenkos Securities Plc (Broker) Tel: +44 (0)20 7397 Russell Kerr/Michael Johnson (Sales) 8900 Callum Davidson/Giles Balleny (Corporate finance)
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPDKQBQOBKDFFB
(END) Dow Jones Newswires
August 25, 2021 02:01 ET (06:01 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions